WEBULL

Abbott (ABT) Lands Exclusive Rights To FDA Approved SimpleScreen In The U.S.

Simply Wall St · 2d ago
  • FDA has approved Freenome's SimpleScreen blood-based colorectal cancer test for average-risk adults.
  • Abbott Laboratories, NYSE:ABT, holds exclusive rights to commercialize SimpleScreen in the U.S.
  • This agreement expands Abbott's colorectal cancer screening portfolio and strengthens its role in blood-based diagnostics.

Abbott Laboratories, NYSE:ABT, is moving into a higher profile position in colorectal cancer screening through this new U.S. commercialization partnership for SimpleScreen. The stock most recently closed at $107.27 and is up 7.6% over the past week and 14.0% over the past month. Over longer horizons, returns have been mixed, with the share price down 13.6% year to date and down 14.3% over the past year.

For investors watching Abbott's MedTech story, SimpleScreen adds a fresh growth angle in a clinically important area without overlapping existing test platforms. This development may influence how the market views Abbott's long term role in cancer screening and broader diagnostics, especially as blood based options gain more attention with both clinicians and average risk adults.

Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.

NYSE:ABT Earnings & Revenue Growth as at Jul 2026
NYSE:ABT Earnings & Revenue Growth as at Jul 2026

3 things going right for Abbott Laboratories that this headline doesn't cover.

The SimpleScreen partnership gives Abbott Laboratories another way to participate in colorectal cancer screening alongside stool based options such as Cologuard. For investors, the key angle is reach. A blood draw can be offered in primary care and routine lab settings, which may broaden access for adults who avoid colonoscopies or stool tests. That fits with Abbott’s focus on diagnostics and MedTech, and comes soon after Q2 2026 results where revenue growth sat next to weaker earnings. SimpleScreen is not a quick fix for those margin pressures, but it does add a new test that can be sold through Abbott’s existing U.S. commercial infrastructure.

How This Fits Into The Abbott Laboratories Narrative

  • The Freenome deal aligns with the narrative focus on higher margin medical technologies and cancer testing as potential growth drivers for Abbott Laboratories.
  • At the same time, building out a new blood based screening category may require higher R&D and commercial spending, which could add to the cost pressures already visible in the most recent earnings.
  • The narrative highlights diabetes and structural heart devices more than cancer blood tests, so the specific competitive dynamics against players such as Guardant Health, Exact Sciences’ broader portfolio and other diagnostics groups may not be fully reflected yet.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Abbott Laboratories to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

  • ⚠️ Abbott Laboratories already faces earnings pressure from higher costs and weaker margins, and ramping up a new test could add to near term expense without immediate profit support.
  • ⚠️ Competition in blood based colorectal cancer screening from companies such as Guardant Health and other diagnostic providers may limit pricing power and share gains.
  • 🎁 The SimpleScreen partnership broadens Abbott Laboratories’ cancer diagnostics offering and can support the push into higher value MedTech and diagnostics highlighted in recent narratives.
  • 🎁 If SimpleScreen is adopted by primary care and average risk adults as an accessible option, it could reinforce Abbott’s position in preventive screening alongside its existing colorectal cancer portfolio.

What To Watch Going Forward

From here, investors may want to watch how quickly Abbott Laboratories secures physician uptake and payer support for SimpleScreen in the U.S. The timing and shape of Medicare and commercial reimbursement, physician guidelines, and any early usage data will help indicate whether the test becomes a meaningful contributor or remains a niche add on. It will also be worth tracking how Abbott balances spending on SimpleScreen against broader margin pressures that showed up in recent earnings, and how competitors in cancer diagnostics respond with their own blood based offerings.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Abbott Laboratories, head to the community page for Abbott Laboratories to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.